Saturday, September 21, 2024
- Advertisement -spot_img

TAG

Ropanicant

Suven’s depression drug shows promise in phase 2a trial; stocks trade flat

Suven Life Sciences announced positive topline results from its Phase 2a proof-of-concept study for Ropanicant (SUVN-911), a novel treatment for moderate to severe...

Latest news

- Advertisement -spot_img